- Home
- YCBD vs ACXP Comparison
YCBD vs ACXP Comparison
Compare YCBD & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YCBD | ACXP |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9M | 6.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | YCBD | ACXP |
|---|---|---|
| Price | $1.04 | $2.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.00 | ★ $143.67 |
| AVG Volume (30 Days) | ★ 2.1M | 50.7K |
| Earning Date | 02-12-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,190,468.00 | N/A |
| Revenue This Year | $6.94 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.47 | $2.33 |
| 52 Week High | $5.49 | $21.00 |
Technical Indicators
Market Signals| Indicator | YCBD | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 52.46 | 31.38 |
| Support Level | $0.72 | $2.51 |
| Resistance Level | $0.82 | $2.78 |
| Average True Range (ATR) | 0.12 | 0.18 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 53.77 | 10.89 |
Price Performance
Historical ComparisonAbout YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.